INTERRELATION BETWEEN THE LEVEL OF THE BIOMARKER ENDOCAN AND THE RISK OF DIABETES MELLITUS TYPE 2 DEVELOPING

Objective: to estimate the level of the biomarker of endothelial dysfunction Endocan and to study its interrelation with the risk of diabetes mellitus type 2 developing. Materials and methods: the cross-sectional trial was conducted among 389 respondents in the East Kazakhstan region, all of them were at the age from 18 to 65. The risk of diabetes mellitus type 2 developing was assessed using the FINDRISK scale. The serum level of the Endocan biomarker was determined by multiplexing investigation an immunofluorescence method using XMap technology. Results and discussion: in assessment the risk of diabetes mellitus type 2, distinguished groups of patients with a low risk of developing diabetes mellitus type 2 included 310 (80%) participants, and a high group of risk of diabetes mellitus type 2 - 79 (20%). The level of the Endocan biomarker significantly prevailed in the group with high risk of the diabetes mellitus type 2 developing in comparison with the low group of risk. A positive direct correlation (r -0.51; р=0,000) was found, statistically significant, indicated the level of the Endocan marker is increasing with an increase the risk of diabetes mellitus type 2 developing. Conclusions: the results of the research identified groups of patients with different risk of diabetes mellitus type 2 developing, detected an increased level of the Endocan biomarker in the high group of risk of diabetes mellitus type 2, and established the interrelation between the increased level of this biomarker of endothelial dysfunction Endocan and the increased risk of diabetes mellitus type 2 developing.

FINDRISK, Endocan biomarker, risk of diabetes, FINDRISK, endothelial dysfunction, Endocan биомаркері, FINDRISK

1. Всемирная организация здравоохранения. Информационный бюллетень. Диабет. Ноябрь 2016. [Электронный ресурс]. - Режим доступа: http://www.who.int/mediacentre/ factsheets/fs312/ru/

2. Мельникова Ю. С. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней /Ю. С. Мельникова, Т. П. Макарова //Казан. мед. журн. - 2015. - Т. 96, №4. - С. 659-660.

3. Национальный регистр Республики Казахстан за 2016 год. [Электронный ресурс]. - Режим доступа: http://www.parlam.kz/ru/ blogs/ferho/Details/ 4/ 20136

4. Перцева Н. О. Состояние эндотелиальной функции у больных сахарным диабетом 2 типа с артериальной гипертонией в условиях хорошей компенсации гипергликемии //Рос. мед.-биол. вестн. им. акад. И. П. Павлова. -2014. - №4. - С. 88-91.

5. Шерьязданова Д. Н. Оценка десятилетнего риска развития сахарного диабета 2 типа в Карагандинской области: популяционное кросс-секционное исследование /Д. Н. Шерьязданова, Е. М. Ларюшина, А. А. Турмухамбетова //Медицина и экология. - 2016. - №2. - С. 64-68.

6. Abduelkarem A. R. Risk calculation of developing type 2 diabetes in Libyan adults /A. R. Abduelkarem, S. I. Sharif, A. M. Hammrouni // Pract. Diab. Int. - 2009. - V. 26. - Pp. 148-151.

7. Alssema M. Finnish questionnaire reasonably good predictor of the incidence of diabetes in The Netherlands /E. J. Feskens, S. J. Bakker, R. T. Gansevoort //Ned. Tijdschr. Geneeskd. - 2008. - №1, Т. 152 (44). - Pp. 2418-2424.

8. Balta S. Endocana novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study /D. P. Mikhailidis, S. Demirkol, C. Ozturk //Angiology. - 2014. - V. 65 (9). - P. 773-777.

9. Balta I. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease /S. Balta, S. Demirkol, D. P. Mikhailidis //Br. J. Dermatol. - 2013. - V. 169 (5). - Pp. 10661070.

10. Balamir I. Association of Endocan, Ischemia-Modified Albumin, and hsCRP Levels With Endothelial Dysfunction in Type 2 Diabetes Mellitus /I. Balamir, I. Ates, C. Topcuoglu // Angiology. - 2018. - V. 69 (7). - Pp. 609-616.

11. Dallio M. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study /M. Dallio, O. Masarone, G. Caprio //J. Gastrointestin. Liver Dis. - 2017. - V. 26 (3). - Pp. 261-268.

12. Daousi C. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors /C. Daousi, I. F. Casson, G. V. Gill //Postgrad. Med. J. - 2006. -V. 82 (966). - Pp. 280-284.

13. Haffner S. M. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome /S. M. Haffner, L. Mykkanen, R. A. Valdez //J. Clin. Endocrinol. Metab. - 1994. - V. 79. - Pp. 1806-1810.

14. Mohieldein A. H. Risk estimation of type 2 Diabetes and dietary habits among adult nondiabetics in central Saudi Arabia /A. H. Mohieldein, M. Alzohairy, M. Hasan //GJHS. -2009. - V. 3. - Pp. 123-133.

15. Mohieldein A. H. Diabetes risk in a Cuban primary care setting in persons with no known glucose abnormalities /A. H. Mohieldein, A. A. Naranjo, A. Y. Rodriguez //MEDICC. - 2013. - V. 15. - Pp. 16-19.

16. Qiu C. R. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients With Acute Myocardial Infarction and Its Clinical Significance /C. R. Qiu, Q. Fu, J. Sui //Angiology. - 2017. - V. 68 (4). - Pp. 354-359.

17. Reaven G. M. Role of insulin resistance in human disease //Diabetes. - 1998. -V. 37. - Pp.1595-1607.

18. Yilmaz M. I. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease /D. Siriopol, M. Saglam, Y. G. Kurt //Kidney Int. - 2014. - V. 86 (6). - Pp. 1213 -1220.